Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: Using B-cell biology to inform therapy

Kieron Dunleavy, Michael Pfreundschuh and Randy Gascoyne • 3 Oct 2015
iwNHL 2015
Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, Homburg, Germany, chairs a discussion with Randy Gascoyne, MD, of the BC Cancer Research Centre, Vancouver, British Columbia, Canada, and Kieron M. Dunleavy, MD, National Cancer Institute, Bethesda, MD. They summarise the biological understanding of the molecular subtypes of diffuse large B-cell lymphoma (DLBCL), including germinal-center B-cell-like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL, and primary mediastinal B-cell lymphoma (PMBL), with an emphasis on diagnostic and rational therapeutic approaches for the management of these patients.

More from Kieron Dunleavy

7:45
Novel targets and agents for lymphoma
John Kuruvilla et al. • 25 Sep 2018
BTK inhibition in primary CNS lymphoma
Kieron Dunleavy • 8 Sep 2017
Ibrutinib in diffuse large B-cell lymphoma
Kieron Dunleavy • 8 Sep 2017
What are the alternatives to R-CHOP in diffuse large B-cell lymphoma?
Kieron Dunleavy • 8 Sep 2017

More from Michael Pfreundschuh

8:13
Describing clonal evolution in lymphoma
Michael Pfreundschuh et al. • 8 Sep 2017
14:40
Update on the clinical management of diffuse large B-cell lymphoma
Christian Gisselbrecht et al. • 5 Sep 2014
23:19
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 2 meeting highlights
Anton Hagenbeek et al. • 9 Apr 2015
26:58
iwNHL 2016: Highlights from Day 2
Anas Younes et al. • 25 Sep 2016

More from Randy Gascoyne

2:20
Lymphoma Microenvironment: biology and therapy (part 2/3)
John Gribben et al. • 5 Sep 2014
5:59
Lymphoma microenvironment: biology and therapy (part 1/3)
John Gribben et al. • 5 Sep 2014
7:27
Lymphoma microenvironment: biology and therapy (part 3/3)
John Gribben et al. • 5 Sep 2014
12:10
12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights
John Gribben et al. • 5 Sep 2014

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals